-
Mashup Score: 1What Courts Are Asking Medicine About Social Media - 4 day(s) ago
This Viewpoint discusses the need for researchers and clinicians to consider questions of legal relevance in designing their studies and communicating their findings to help in developing policies regarding social media to improve children’s well-being.
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
This randomized clinical trial compares the efficiency of prescreening patients with heart failure using an artificial intelligence (AI) large language model for inclusion in a clinical trial vs manual prescreening.
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet-
AI-assisted patient screening improved the rate of eligibility determination and enrollment compared with manual screening in a heart failure trial. https://t.co/PEfiL4dhIp @AJBloodMD @ozanunlumd https://t.co/QU8lp0KnbZ
-
-
Mashup Score: 4Second Legacy of Henrietta Lacks - 4 day(s) ago
This Viewpoint considers unjust enrichment stemming from the use of biospecimens known as offering particular value without informing the patient or gaining consent, as in the case of Henrietta Lacks.
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet-
This Viewpoint considers unjust enrichment stemming from the use of biospecimens known as offering particular value without informing the patient or gaining consent, as in the case of Henrietta Lacks. https://t.co/bbV5KMBTCj https://t.co/OTcMIi4yXc
-
-
Mashup Score: 1Evaluating Treatments for Amyotrophic Lateral Sclerosis - 5 day(s) ago
The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD.
Source: edhub.ama-assn.orgCategories: General Medicine News, General HCPsTweet-
@JAMANetworkOpen @JAMANeuro The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni discusses this platform trial with JAMA Deputy Editor Christopher Muth. https://t.co/bcRFWKThHh
-
-
Mashup Score: 0Platform Trials in ALS - 5 day(s) ago
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive weakness of voluntary muscle. ALS is uncommon but not rare, with a lifetime risk of about 1 in 400.1 Nearly all patients with ALS will die from ALS, most from respiratory failure, and the median…
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet-
@JAMANetworkOpen @JAMANeuro "The HEALEY ALS platform is a courageous and innovative first attempt at platform trials in ALS." Read the Editorial. https://t.co/iec54WVE7M https://t.co/RtLgiHFWnE
-
-
Mashup Score: 2
This Guide to Statistics and Methods provides an overview of platform trials, describes the characteristics that make them more efficient for evidence generation, and discusses their limitations.
Source: jamanetwork.comCategories: General Medicine News, Critical CareTweet-
@JAMANetworkOpen @JAMANeuro This JAMA Guide to Statistics and Methods provides an overview of platform trials, describes the characteristics that make them more efficient for evidence generation, and discusses their limitations. https://t.co/uyNe9uOEMn https://t.co/tqxsbZOfeF
-
-
Mashup Score: 2Verdiperstat in Amyotrophic Lateral Sclerosis - 5 day(s) ago
This randomized clinical trial investigated the effect of verdiperstat, a myeloperoxidase inhibitor, in amyotrophic lateral sclerosis.
Source: jamanetwork.comCategories: General Medicine News, Critical CareTweet-
@JAMANetworkOpen From @JAMANeuro: Treatment with verdiperstat was unlikely to alter disease progression in amyotrophic lateral sclerosis. https://t.co/8OEJKLIxpz https://t.co/A9H9QC1L5W
-
-
Mashup Score: 1
This randomized clinical trial evaluates the safety, tolerability, and efficacy of zilucoplan in patients with amyotrophic lateral sclerosis.
Source: jamanetwork.comCategories: General Medicine News, Critical CareTweet-
From @JAMANetworkOpen: RCT: Zilucoplan, a complement inhibitor targeting C5, did not impact the progression in patients with ALS. https://t.co/YTWzn0WUQF https://t.co/q7et3z4ycB
-
-
Mashup Score: 0Pridopidine in Amyotrophic Lateral Sclerosis - 5 day(s) ago
This randomized platform trial investigates whether pridopidine, a sigma-1 receptor agonist, impacted disease progression among patients with amyotrophic lateral sclerosis.
Source: jamanetwork.comCategories: General Medicine News, Critical CareTweet-
Pridopidine did not impact the progression of amyotrophic lateral sclerosis in this 24-week study. https://t.co/zoUPk1HGoT https://t.co/gM0CkJxyTz
-
-
Mashup Score: 0CNM-Au8 in Amyotrophic Lateral Sclerosis - 5 day(s) ago
This randomized, multicenter platform trial investigates the efficacy of CNM-Au8, an oral suspension of catalytically active gold particles, on the disease progression of patients with amyotrophic lateral sclerosis.
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet-
🧵 CNM-Au8, an oral suspension of catalytically active gold particles, did not improve the primary efficacy outcome of amyotrophic lateral sclerosis disease progression. https://t.co/ZHICiQ8VGT https://t.co/vz7pwrepzk
-
Viewpoint: Courts are increasingly looking to the medical field for answers as they adjudicate cases involving social media's impact on children's mental health and newly enacted child protection laws. https://t.co/JamfyE679v @mjblawrence https://t.co/PBxC2Om8Fu